@article{43c99f1ecb344b148d571e7c8b02c64d,
title = "Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response",
abstract = "Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor{\texttrademark} PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor{\texttrademark} system merits further investigation in this setting.",
keywords = "CML BCR-ABL, Minimal residual disease, Molecular diagnostics, Nilotinib",
author = "O'Dwyer, {Michael E.} and Ronan Swords and Arnon Nagler and McMullin, {Mary Frances} and {le Coutre}, {Philipp D.} and Langabeer, {Stephen E.} and Alberto Alvarez-Iglesias and Hongxin Fan and Woodman, {Richard C.} and Giles, {Francis J.} and Eibhlin Conneally",
note = "Funding Information: MEOD, RS, AN, FJG, PDLC, MFMM and EC have consulted for, and received research funding from, Novartis. RCW is a Novartis employee and stockholder. Funding Information: This work was supported by free drug and a grant from Novartis . Funding Information: The authors would like to acknowledge Dr. Martin Mueller for PCR reporting conducted in Mannheim, Germany, Dr. Yulia Volchek, Chaim Sheba, the research nurse coordinators at each site, Veronica McInerney, Galway, Peggy Grille, Berlin, Gila Buchman, Chaim Sheba, Kathy Cobb, San Antonio, Peig Carroll, Dublin. This study was sponsored by the All Ireland Cooperative Oncology Research Group (ICORG). We would particularly like to acknowledge Marzena Wieczorkowska, Emma Kent, Brian Moulton and colleagues at ICORG, Dublin, Ireland for their support in running the study. The study drug and running costs were provided by Novartis. The Xpert analysis was part funded by Cepheid.",
year = "2014",
month = mar,
doi = "10.1016/j.leukres.2013.11.016",
language = "English (US)",
volume = "38",
pages = "310--315",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "3",
}